Arcutis Biotherapeutics, Inc. (ARQT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 993.51M |
| Enterprise value | 927.57M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 10.00 |
| Price/book (mrq) | 11.21 |
| Enterprise value/revenue | 15.56 |
| Enterprise value/EBITDA | -4.07 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.14 |
| 52-week change 3 | -40.93% |
| S&P500 52-week change 3 | 22.43% |
| 52-week high 3 | 15.12 |
| 52-week low 3 | 1.76 |
| 50-day moving average 3 | 10.09 |
| 200-day moving average 3 | 6.47 |
Share statistics
| Avg vol (3-month) 3 | 3.87M |
| Avg vol (10-day) 3 | 2.22M |
| Shares outstanding 5 | 115.53M |
| Implied shares outstanding 6 | 115.53M |
| Float 8 | 74.9M |
| % held by insiders 1 | 2.48% |
| % held by institutions 1 | 95.87% |
| Shares short (15 Apr 2024) 4 | 19.66M |
| Short ratio (15 Apr 2024) 4 | 5.09 |
| Short % of float (15 Apr 2024) 4 | 20.63% |
| Short % of shares outstanding (15 Apr 2024) 4 | 17.10% |
| Shares short (prior month 15 Mar 2024) 4 | 14.99M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -452.23% |
Management effectiveness
| Return on assets (ttm) | -38.12% |
| Return on equity (ttm) | -175.79% |
Income statement
| Revenue (ttm) | 59.61M |
| Revenue per share (ttm) | 0.86 |
| Quarterly revenue growth (yoy) | 356.80% |
| Gross profit (ttm) | N/A |
| EBITDA | -239.58M |
| Net income avi to common (ttm) | -262.14M |
| Diluted EPS (ttm) | -3.78 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 271.86M |
| Total cash per share (mrq) | 2.81 |
| Total debt (mrq) | 205.92M |
| Total debt/equity (mrq) | 232.24% |
| Current ratio (mrq) | 7.08 |
| Book value per share (mrq) | 0.92 |
Cash flow statement
| Operating cash flow (ttm) | -247.06M |
| Levered free cash flow (ttm) | -151.32M |
© 2024 Yahoo. All rights reserved.